Tony oversees Arronax’s partnerships

Tony oversees Arronax’s partnerships

Developing Arronax's links with the business world is the mission entrusted to Tony Prézeau as the new director of technology transfer. One week after his arrival at Arronax, Tony Prézeau (…)
Read more
End of Ipsen clinical trial at 177lu-OPS201

End of Ipsen clinical trial at 177lu-OPS201

Launched in November 2018 in Nantes, France, the phase 1-2 study evaluating the safety, tolerability and efficacy of 177lu-OPS201 in patients with somatostatin receptor-positive neuroendocrine tumors is nearing completion. The (…)
Read more
A medical first in Nantes!

A medical first in Nantes!

On 23 May 2019, a patient treated at the Institut de Cancérologie de l’Ouest (ICO) for a tumor of the rectum received a dose of 64Cu-ATSM for an imagery examination. This medical (…)
Read more